FR167653, a p38 mitogen-activated protein kinase inhibitor, aggravates experimental colitis in mice

Figure 1 Changes in body weight (A) and survival rate (B). Mice were fed DSS and injected intraperitoneally with vehicle (PBS) or FR167653 (30 mg/kg per day) daily starting at d 0. The weight of individual mice was followed daily. Data represent mean ± SE (n = 8 mice/group). ^aP < 0.05, FR167653 vs vehicle (PBS).

Figure 2 Pictures of laparotomy (upper part) and resected colon (lower part). On day 14, in the FR167653-treated DSS mice stool softening and colon shortening were remarkable, as compared to the vehicle (PBS)-treated DSS mice.

Figure 3 Effects of FR167653 on colon length (A), disease activity index (B), and histological score (C) at day 14. The criteria of scoring are described in Materials and Methods. Data represent mean ± SE (n = 8 mice/group), ^aP < 0.05.

Figure 4 Histological analyses for FR167653 effects on DSS colitis. Colons were excised after 14 d of DSS treatment and stained with HE, anti-CD4 antibody, and anti-F4/80 antibody.

Figure 5 RT-PCR analysis of mucosal cytokine expression in DSS colitis. Representative results of 5 independent experiments are presented.